FDA approves zavegepant (ZAVZPRET™), the first nasal spray of its kind for acute treatment of migraine with or without aura.
Pfizer announced this morning that zavegepant (ZAVZPRET™) has now been approved by the U.S. Food and Drug Administration (FDA) for treating migraine—with or without aura in adults. As the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, zavegepant is a breakthrough for people living with migraine who need alternative treatment options to oral medicines.
Pfizer is anticipating that zavegepant will be available in pharmacies in July 2023.
People living with migraine benefit when there are more treatment options available to them based on their individual needs. The American Migraine Foundation is dedicated to providing the latest news and resources on new treatment for migraine as they become available.
Read Pfizer’s full press release for more information.
The American Migraine Foundation is committed to improving the lives of those living with this debilitating disease. To learn more about all of your migraine treatment options, visit the AMF Resource Library. For help finding a healthcare provider, check out our Find a Doctor tool. Together, we are as relentless as migraine.
